Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade

@article{Mller2015TrastuzumabE,
  title={Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade},
  author={Philipp A. M{\"u}ller and Matthias Kreuzaler and Tarik Khan and Daniela S Thommen and Kea Martin and Katharina Glatz and Spasenija Savic and Nadia Harbeck and Ulrike Anneliese Nitz and Oleg Gluz and Michael S. von Bergwelt-Baildon and Hans Kreipe and Sai T. Reddy and Matthias Christgen and Alfred Zippelius},
  journal={Science Translational Medicine},
  year={2015},
  volume={7},
  pages={315ra188-315ra188}
}
Targeted drug delivery with antibody-drug conjugates such as the HER2-directed ado-trastuzumab emtansine (T-DM1) has emerged as a powerful strategy for cancer therapy. We show that T-DM1 is particularly effective in eliciting antitumor immunity in patients with early breast cancer (WSG-ADAPT trial) and in a HER2-expressing orthotopic tumor model. In the latter, despite primary resistance to immunotherapy, combined treatment with T-DM1 and anti–CTLA-4/PD-1 (cytotoxic T lymphocyte–associated… CONTINUE READING